<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13636">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02929407</url>
  </required_header>
  <id_info>
    <org_study_id>000249</org_study_id>
    <secondary_id>2016-001078-13</secondary_id>
    <nct_id>NCT02929407</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Effect of the Study Drug (FE 204205) in Patients With Cirrhotic Portal Hypertension</brief_title>
  <official_title>A Placebo Controlled, Double-blind, Randomised Trial Investigating Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics After Intravenous Administration of FE 204205 in Patients With Cirrhotic Portal Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to investigate safety, tolerability, pharmacodynamics, and
      pharmacokinetics after intravenous administration of FE 204205 in patients with cirrhotic
      portal hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">February 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>From baseline (pre-dose) to 2 hours after start of infusion</time_frame>
    <description>Measured by hepatic vein catheterization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type, frequency and intensity of Adverse Events</measure>
    <time_frame>Up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>From baseline (pre-dose) up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma lactate levels</measure>
    <time_frame>From baseline (pre-dose) to 3 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum concentration observed (Cmax)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5 and 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve to infinity (AUC)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5 and 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Total systemic clearance (CL)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5 and 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Elimination half-life (t1/2)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5 and 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Volume of distribution associated with the terminal phase (Vz)</measure>
    <time_frame>Pre-dose, 0.5, 1, 2, 3, 4, 5 and 6 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in ECG parameters</measure>
    <time_frame>From baseline (pre-dose) up to Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood gas (PaO2)</measure>
    <time_frame>From baseline (pre-dose) to 3 hours after start of infusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood gas (PaCO2)</measure>
    <time_frame>From baseline (pre-dose) to 3 hours after start of infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>FE 204205</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 204205</intervention_name>
    <arm_group_label>FE 204205</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-65 years of age

          -  Verified cirrhotic portal hypertension

        Exclusion Criteria:

          -  Co-existing disease e.g. significant organ failure and decompensated cirrhosis

          -  Type 1 hepatorenal syndrome

          -  Acute-on-chronic liver failure

          -  Hepatic encephalopathy ≥grade 2

          -  Hepatocellular carcinoma

          -  History of underlying chronic heart disease

          -  Use of vasopressin or terlipressin within 7 days prior to dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Development Support</last_name>
    <email>DK0-Disclosure@ferring.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona, Departamento hepatología</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 7, 2017</lastchanged_date>
  <firstreceived_date>September 13, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
